Medical Therapy for Cushing’s Syndrome in the Twenty-first Century

• Autores: Nicholas A. Tritos, Beverly M.K. Biller
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 47, Nº. 2, 2018 (Ejemplar dedicado a: Cushing's Syndrome), págs. 427-440
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • rompt control of hypercortisolism is needed to reverse clinical and biochemical man- ifestations and decrease excess morbidity and mortality in patients with endogenous Cushing’s syndrome (CS).

    Resection of the underlying tumor is currently the mainstay of treatment of CS.

    After trans-sphenoidal pituitary surgery, persistent or recur- rent hypercortisolism may occur in, respectively, 10% to 20% and 20% to 30% of patients with pituitary corticotroph adenomas (ie, Cushing’s disease [CD]), which